Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  tanespimycin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 27 for your search:
Start Over
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA200-003, KAG-302, NCT00514371
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA200-004, KAG-301, NCT00546780
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 040238, 04-C-0238, NCI-04-C-0238, 6399, NCI-6399, NCT00089375, NCT00088374
Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Metastatic Papillary or Clear Cell Renal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-04082, 6479, NCI-6479, NCT00093405
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00052, CDR0000388036, NCI-6307, MAYO-MC0362, MC0362, 6307, P30CA015083, N01CM62205, NCT00093496
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03058, C-2803, U01CA062502, U01CA062487, CDR0000391198, WSU-C-2803, 6552, NCI-6552, NCT00096109
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00063, JHOC-B/06/174, NCI-6482, JHOC-JS0652, CDR0000433150, MC0476, 6482, N01CM62205, P30CA015083, N01CM62207, MAYO-MC0476, NCT00118248
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01466, MAYO-MC0453, NCI-6651, CDR0000433492, MC0453, 6651, N01CM62205, NCT00118092
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 16
Sponsor: NCI
Protocol IDs: NCI-2009-00101, CDR0000433593, 2004-0792, 6936, P30CA016672, R21CA117070, MDA-2004-0792, NCI-6936, NCT00117988
Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Systemic Mastocytosis
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0076, 6454, NCI-6454, NCI-P6175, NCT00132015
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00156, MC0542, CDR0000445454, N01CM17104, MAYO-MC0542, 7351, NCI-7351, NCT00577889
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067283, U01CA069912, P30CA015083, 990102, MAYO-990102, NCI-T99-0058, T99-0058, NCT00004075
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02315, PCI-99-020, U01CA099168, CDR0000067486, NCI-T99-0038, T99-0038, NCT00004241
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01429, MC0111, MAYO-MC0111, CDR0000257247, NCI-5291, U01CA069912, 5291, NCT00047047
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01436, NCI-5878, CDR0000287199, MSKCC-03006, 03-006, 5878, P30CA008748, U01CA069856, NCT00058253
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000315521, U01CA062487, P30CA022453, WSU-C-2599, NCI-5932, 5932, NCT00066326
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-2012-01811, ADVL0316, CDR0000355714, COG-ADVL0316, U01CA097452, NCT00079404
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02610, PCI-03-152, U01CA099168, U01CA062502, CDR0000373824, PCI-IRB-0403094, 6494, NCI-6494, NCT00087217
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and under at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2012-01456, 04-069, POETIC-MSKCC-04069, CDR0000391010, NCI-6323, MSKCC-04069, U01CA069856, 6323, NCT00093821
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00056, NCI-6383, CDR0000401509, MC0313, 6383, U01CA070095, U01CA069912, MAYO-MC0313, NCT00098423
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01467, 05-017, MSKCC-IRB-05017, NCI-7009, CDR0000434501, U01CA069856, 7009, NCT00119236
Start Over